Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 3

2(25.0%)

N/A

1(12.5%)

8Total

Phase 2(5)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07514936Phase 2Recruiting

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

Role: collaborator

NCT07577050Phase 2Not Yet Recruiting

A Phase II Study of NB001 for Acute Migraine Treatment

Role: collaborator

NCT06928376Phase 2Recruiting

A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

Role: collaborator

NCT06084819Phase 2Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Role: collaborator

NCT06068621Phase 2Completed

Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

Role: collaborator

NCT05524389Phase 3Not Yet Recruiting

Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions

Role: collaborator

NCT03955367Phase 3Unknown

Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer

Role: collaborator

NCT02982668Not ApplicableTerminated

Optimizing Early Enteral Nutrition in Severe Stroke

Role: collaborator

All 8 trials loaded